PRP in ACLR to Prevent PTOA
Platelet Rich Plasma (PRP) Treatment of the Anterior Cruciate Ligament Injured Knee to Decrease the Risk of Post-traumatic Osteoarthritis (PTOA): a Randomized Double-blind Controlled Trial
Hospital for Special Surgery, New York
56 participants
Jun 27, 2022
INTERVENTIONAL
Conditions
Summary
The purpose of our study is to examine the effect of platelet-rich-plasma (PRP) injection on the short-term resolution of post-injury inflammation (biomarkers) and improvement in joint function in patients with acute ACL injury. This RCT has been powered based on the questionnaire KOOS Jr. but it is considered a 'pilot study' in terms of the lab analysis proposed.
Eligibility
Inclusion Criteria4
- Acute ACL injury within 6 weeks of presentation
- Age 14-50
- Male or female
- Meniscus injury that can be treated with meniscectomy or repair (the lack of meniscus injury will not exclude patients)
Exclusion Criteria9
- Prior ACL reconstruction
- Prior cartilage repair procedure
- Prior meniscus surgery within 12 months
- Prior steroid, hyaluronic acid, or PRP injection within 6 months
- Other ligament injury requiring repair
- Any cartilage lesion requiring repair
- Any cartilage lesion greater than grade 2 (partial thickness injury)
- History of inflammatory arthritis or joint sepsis
- Non English speakers
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
We aim to evaluate early catabolic and inflammatory changes in knee joints in patients receiving PRP injections following ACL injury, as these patients are at higher risk of developing PTOA. We also aim to establish correlations between markers of biologic activity of PRP and clinical outcomes (including both patient-reported outcomes and clinical functional outcomes), with emphasis on cellular and molecular inflammatory parameters modulated by PRP.
Patients randomized into the control arm will receive the placebo or saline injection
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05412381